Juan Antonio Jiménez Barceló
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juan Antonio Jiménez Barceló has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Aina Ruiz Romero
Hospital Son Llàtzer
1 shared publication- Albert Tubau
Servicio de Ginecología y Obstetricia, Hospital Universitario Son Llàtzer, 07198 Palma, Balearic Islands, Spain
1 shared publication Albert Tubau Navarra
Hospital Son Llàtzer
1 shared publicationAlexander Damià Heine-Suñer
Fundacio Institut d'Investigacio Sanitaria Illes Balears
1 shared publicationAna Briceño-Hinojo
Department of Cardiology, Hospital Universitario Puerta de Hierro Majadahonda, IDIPHISA , Manuel de Falla, 2, Madrid 28222
1 shared publication- Ana Isabel Fernández
Cardiology Department, Hospital General Universitario Gregorio Marañón, IiSGM (A.I.F.-A.).
1 shared publication
Latest Publications
- Open Access
- 10 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Incremental yield of genetic retesting in hypertrophic cardiomyopathy
Background and Aims: Modern genetic testing in hypertrophic cardiomyopathy (HCM) includes newly described HCM-associated genes and full intronic regions of certain classic sarcomeric genes. This study evaluated genetic retesting in HCM patients with a prior negative test and identified predictors of a positive result to guide retesting. Methods: This multicentre study included patients with HCM who previously had negative next-generation sequencing (NGS)-based genetic testing at four centres. Subjects were retested using an updated NGS-based HCM panel. Results: Of 508 retested HCM patients (median age 70 years; 66.9% male; median maximal left ventricular wall thickness 18 mm; median interval from initial genetic test 6.6 years), 46 (9%) had 48 HCM-related variants: 14 in new HCM-associated genes, 3 in deep intronic MYBPC3 regions, 18 intermediate-effect variants, and 13 (8 reclassified) in classic HCM-associated genes. In multivariable analysis, the presence of late gadolinium enhancement (LGE) [odds ratio (OR) 3.52; 95% confidence interval (CI) 1.38–10.25], the Mayo HCM score (OR 1.46 per 1 point increase; 95% CI 1.08–2.01), and the Toronto HCM score (OR 1.18 per 1 point increase; 95% CI 1.08–1.30) were independent predictors of detecting HCM-related variants at retesting. The diagnostic yields in patients with LGE and a high Toronto score (≥13 points), and with LGE and a high Mayo score (≥4 points), were 80% and 50%, respectively. Conclusions: In patients with HCM and prior negative genetic testing, retesting identified HCM-related variants in 9% of individuals, allowing counselling and risk stratification. Late gadolinium enhancement, combined with the Mayo and Toronto scores, may be used to guide which patients should be prioritized for genetic retesting.
- 10 November 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Open AccessIncremental yield of genetic retesting in hypertrophic cardiomyopathy
Background and Aims: Modern genetic testing in hypertrophic cardiomyopathy (HCM) includes newly described HCM-associated genes and full intronic regions of certain classic sarcomeric genes. This study evaluated genetic retesting in HCM patients with a prior negative test and identified predictors of a positive result to guide retesting. Methods: This multicentre study included patients with HCM who previously had negative next-generation sequencing (NGS)-based genetic testing at four centres. Subjects were retested using an updated NGS-based HCM panel. Results: Of 508 retested HCM patients (median age 70 years; 66.9% male; median maximal left ventricular wall thickness 18 mm; median interval from initial genetic test 6.6 years), 46 (9%) had 48 HCM-related variants: 14 in new HCM-associated genes, 3 in deep intronic MYBPC3 regions, 18 intermediate-effect variants, and 13 (8 reclassified) in classic HCM-associated genes. In multivariable analysis, the presence of late gadolinium enhancement (LGE) [odds ratio (OR) 3.52; 95% confidence interval (CI) 1.38–10.25], the Mayo HCM score (OR 1.46 per 1 point increase; 95% CI 1.08–2.01), and the Toronto HCM score (OR 1.18 per 1 point increase; 95% CI 1.08–1.30) were independent predictors of detecting HCM-related variants at retesting. The diagnostic yields in patients with LGE and a high Toronto score (≥13 points), and with LGE and a high Mayo score (≥4 points), were 80% and 50%, respectively. Conclusions: In patients with HCM and prior negative genetic testing, retesting identified HCM-related variants in 9% of individuals, allowing counselling and risk stratification. Late gadolinium enhancement, combined with the Mayo and Toronto scores, may be used to guide which patients should be prioritized for genetic retesting.
- Open Access
- 30 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10595
Maternal Genotype and Dietary Vitamin A Modify Aortic Arch Phenotypes in a Mouse Model of 22q11DS
Congenital heart defects (CHDs) occur in 50–75% of patients with 22q11.2 deletion syndrome (22q11.2DS), ranging from mild to severe manifestations. The genetic and environmental factors contributing to variable CHD phenotypes in 22q11.2DS are largely unknown. In this study, we used a mouse model of 22q11.2DS, termed Df1/+, to evaluate the effect of maternal vitamin A (VitA) dietary imbalance (supplementation or deficiency) on the incidence of aortic arch defects (AADs), which is a common type of CHD observed in both 22q11.2DS patients and Df1/+ mouse embryos. While most groups showed a previously observed 30% AAD incidence, two groups exhibited significantly higher rates: (1) Df1/+ embryos from WT mothers on a VitA-Supl diet (51% AADs) and (2) Df1/+ embryos from Df1/+ mothers on a VitA-Def diet (45% AADs). Thus, a low or high maternal VitA diet can increase the frequency of AADs in embryos depending on the maternal genotype. Transcriptomic analysis of the hearts of these high-risk embryos at embryonic day (E)18.5 revealed downregulation of key genes (Hdac3, Ptgds, Sirt5, Pfkm, and Lclat1) associated with energy metabolism pathways, such as oxidative phosphorylation and glycolysis, suggesting impaired cardiac recovery mechanisms. In conclusion, our findings demonstrate that altered VitA exposure can exacerbate AAD incidence in a maternal-genotype-dependent manner, highlighting the complex interplay between embryonic and maternal genetic background and environmental factors in CHDs associated with 22q11.2DS.
- 30 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (21) , 10595
Open AccessMaternal Genotype and Dietary Vitamin A Modify Aortic Arch Phenotypes in a Mouse Model of 22q11DS
Congenital heart defects (CHDs) occur in 50–75% of patients with 22q11.2 deletion syndrome (22q11.2DS), ranging from mild to severe manifestations. The genetic and environmental factors contributing to variable CHD phenotypes in 22q11.2DS are largely unknown. In this study, we used a mouse model of 22q11.2DS, termed Df1/+, to evaluate the effect of maternal vitamin A (VitA) dietary imbalance (supplementation or deficiency) on the incidence of aortic arch defects (AADs), which is a common type of CHD observed in both 22q11.2DS patients and Df1/+ mouse embryos. While most groups showed a previously observed 30% AAD incidence, two groups exhibited significantly higher rates: (1) Df1/+ embryos from WT mothers on a VitA-Supl diet (51% AADs) and (2) Df1/+ embryos from Df1/+ mothers on a VitA-Def diet (45% AADs). Thus, a low or high maternal VitA diet can increase the frequency of AADs in embryos depending on the maternal genotype. Transcriptomic analysis of the hearts of these high-risk embryos at embryonic day (E)18.5 revealed downregulation of key genes (Hdac3, Ptgds, Sirt5, Pfkm, and Lclat1) associated with energy metabolism pathways, such as oxidative phosphorylation and glycolysis, suggesting impaired cardiac recovery mechanisms. In conclusion, our findings demonstrate that altered VitA exposure can exacerbate AAD incidence in a maternal-genotype-dependent manner, highlighting the complex interplay between embryonic and maternal genetic background and environmental factors in CHDs associated with 22q11.2DS.
- Open Access
- 12 July 2025
- Published by Wiley
Real-World Application of Trio-Based Exome Sequencing in Prenatal Genetic Diagnosis: a prospective study
Design Prospective cohort study. Objective We assessed the diagnostic yield of trio-based WES (fetus and both parents) in pregnancies with sonographic findings and prior negative results from quantitative fluorescent PCR (QF-PCR), conducted in parallel with CMA. Settings Prenatal genetic testing was conducted within the public health system of the Balearic Islands, Spain. Testing was performed at the Molecular Diagnostics and Clinical Genetics Unit at Hospital Universitari Son Espases, with samples from multiple regional hospitals. Population or samples Trio samples from 249 pregnancies with ultrasound fetal structural anomalies. Methods Parallel trio-based WES and CMA were performed. Molecular findings were classified, and diagnostic yield was analyzed across anomaly categories. Clinical management outcomes were also recorded. Main Outcome Measures Diagnostic yield of trio-based WES and its influence on clinical management. Results A molecular diagnosis was established in 26.9% (67/249) of cases. Variant distribution included 58.2% de novo autosomal-dominant, 29.9% autosomal-recessive, 9.0% inherited dominant, and 3.0% X-linked. Diagnostic yield varied by anomaly category, ranging from 37.5% in growth disorders to 6.3% in gastrointestinal anomalies. The median turnaround time was 12 days. Pregnancy termination occurred in 54.7% of diagnosed cases compared to 18.1% among those without a diagnosis. Conclusions Prenatal parallel trio-based WES and CMA following negative QF-PCR results could represent an appropriate and actionable strategy in the current prenatal diagnostic landscape. This approach provides a significantly improved diagnostic yield and faster turnaround time, thereby delivering meaningful support to families facing complex prenatal decision-making. Funding The authors did not receive support from any organization. Keywords: Microarray Analysis; Exome Sequencing; Ultrasonography, Prenatal; Clinical Decision‑Making; Prenatal Diagnosis.
- 12 July 2025
- Published by Wiley
Open AccessReal-World Application of Trio-Based Exome Sequencing in Prenatal Genetic Diagnosis: a prospective study
Design Prospective cohort study. Objective We assessed the diagnostic yield of trio-based WES (fetus and both parents) in pregnancies with sonographic findings and prior negative results from quantitative fluorescent PCR (QF-PCR), conducted in parallel with CMA. Settings Prenatal genetic testing was conducted within the public health system of the Balearic Islands, Spain. Testing was performed at the Molecular Diagnostics and Clinical Genetics Unit at Hospital Universitari Son Espases, with samples from multiple regional hospitals. Population or samples Trio samples from 249 pregnancies with ultrasound fetal structural anomalies. Methods Parallel trio-based WES and CMA were performed. Molecular findings were classified, and diagnostic yield was analyzed across anomaly categories. Clinical management outcomes were also recorded. Main Outcome Measures Diagnostic yield of trio-based WES and its influence on clinical management. Results A molecular diagnosis was established in 26.9% (67/249) of cases. Variant distribution included 58.2% de novo autosomal-dominant, 29.9% autosomal-recessive, 9.0% inherited dominant, and 3.0% X-linked. Diagnostic yield varied by anomaly category, ranging from 37.5% in growth disorders to 6.3% in gastrointestinal anomalies. The median turnaround time was 12 days. Pregnancy termination occurred in 54.7% of diagnosed cases compared to 18.1% among those without a diagnosis. Conclusions Prenatal parallel trio-based WES and CMA following negative QF-PCR results could represent an appropriate and actionable strategy in the current prenatal diagnostic landscape. This approach provides a significantly improved diagnostic yield and faster turnaround time, thereby delivering meaningful support to families facing complex prenatal decision-making. Funding The authors did not receive support from any organization. Keywords: Microarray Analysis; Exome Sequencing; Ultrasonography, Prenatal; Clinical Decision‑Making; Prenatal Diagnosis.